inVentiv Health

Campbell Alliance launches market research and analytics group

Wednesday, March 21, 2012 11:42 AM

Campbell Alliance, an inVentiv Health company and management consulting firm, has launched Encuity Research, the firm's market research and analytics subsidiary.

More... »


inVentiv to acquire Kforce

Monday, March 19, 2012 12:39 PM

Burlington, Mass.-based inVentiv Health, which offers clinical, commercial and consulting services to the healthcare industry, has signed a definitive agreement to acquire Kforce Clinical Research (KCR), a provider of functional outsourcing solutions to pharmaceutical, biotech and medical device companies, from Kforce Inc. for $50 million in cash.

More... »


inVentiv's iHCE establishes headquarters in London

Wednesday, March 14, 2012 11:01 AM

Switzerland-based inVentiv Health Communications/Europe (iHCE), an inVentiv Health company, is opening its new operational headquarters in London to serve as a hub for all European offices and support the rapid growth of the company’s consolidated communications business.

More... »

inVentiv Health launches multichannel marketing company MySTRO

Thursday, March 8, 2012 12:34 PM

Burlington, Mass.-based inVentiv Health, which provides clinical, commercial and consulting services to the healthcare industry, has launched MySTRO, a multichannel marketing and sales solutions company. MySTRO provides sales force support, telephone and remote personal selling, print and direct mail, sample accountability and compliance services.

More... »

ASLAN selects PharmaNet/i3 as strategic partner for oncology development

Tuesday, March 6, 2012 01:30 PM

ASLAN Pharmaceuticals has selected PharmaNet/i3, inVentiv Health’s clinical segment, as a strategic partner supporting the development of its oncology portfolio in Asia and conducting phase I and phase II clinical trials for two of ASLAN’s compounds.

More... »

The CenterWatch Monthly, March 2012

Thursday, March 1, 2012 06:05 AM

Living in a post-M&A world of CROs

More... »

Stephan Henauer to head i3 Pharma Resourcing in Europe

Monday, February 6, 2012 02:52 PM

PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Stephan Henauer, M.D., executive director of i3 Pharma Resourcing. Henauer will lead the company’s staffing business in central, eastern and northern Europe.

More... »

inVentiv Health to acquire SDI businesses from IMS Health

Friday, January 20, 2012 02:53 PM

Burlington, Mass.-based inVentiv Health will acquire certain promotional and medical audit businesses of SDI Health, which IMS Health has committed to divest in connection with obtaining regulatory approval of its acquisition of SDI.  Financial terms were not disclosed.

More... »

Pharmaceutical Institute integrates Preceptiv Learning Solutions

Friday, January 13, 2012 12:00 PM

Pharmaceutical Institute has now fully integrated Preceptiv Learning Solutions into its operations, both subsidiaries of inVentiv Health.

More... »

inVentiv expands services to Korea

Thursday, November 10, 2011 09:28 AM

inVentiv Health has established inVentiv Health Korea, a Seoul-based operation that will provide clinical development and commercial services to healthcare clients.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs